We Don't Need More Reasons to Reject Heritable Genome Modification
By Katie Hasson,
The Hill
| 06. 10. 2019
Late last year, scientist He Jiankui announced the birth of the world’s first genetically modified babies. He deployed a technology known as CRISPR to alter the genomes of two embryos that he used to initiate a pregnancy; their mother carried the pregnancy until the two girls, publicly called Lulu and Nana, were delivered prematurely by C-section.
The response of scientists, bioethicists, and the public was immediate and overwhelmingly negative. He’s reckless actions violated Chinese regulations, crossed a bright line that dozens of countries have written into their laws, flouted nearly every rule of medical ethics, and exposed two girls to grave and unknowable risks.
This week, a study emerged highlighting the dangers of what He did, especially based on our current level of understanding. He attempted to disable a gene called CCR5 by producing a variant that has been shown to confer resistance to HIV. But the new study suggests that having non-working copies of CCR5 actually has an overall negative effect on health, specifically a 21 percent increase in mortality before age 76.
These findings...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...